| Therapeutic | Volrustomig |
| Target 1 | CTLA4/CD152 |
| Heavy Chain 1 | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS |
| Light Chain 1 | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK |
| 100% seqID Fv 1 Structure | 5ggu [Fvs: AB, HL], 5ggv [Fvs: HL] |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | PDCD1/CD279/PD1 |
| Heavy Chain 2 | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS |
| Light Chain 2 | QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
| 100% seqID Structure [Fv 1] | 5ggu [Fvs: AB, HL] |
| 100% seqID Structure [Fv 1] | 5ggv [Fvs: HL] |
| There are no identical PDB matches to at least one Fv in this therapeutic. Click the links to build models with ABodyBuilder2: [Fv 1] [Fv 2] |
Follow these links to our prediction tools:
| Format | Bispecific mAb |
| Isotype | G1 |
| Highest Clinical Trial (Aug '24) | Phase-III |
| Estimated Status | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2022 |
| INN Year Recommended | None |
| Companies Involved | AstraZeneca |
| Conditions Approved | na |
| Conditions Active | Solid tumours, Renal cell carcinoma |
| Conditions Discontinued | na |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
